<DOC>
	<DOCNO>NCT00420836</DOCNO>
	<brief_summary>This study assess aerosol delivery characteristic ( measure nebulization time , serum sputum tobramycin pharmacokinetic parameter ) safety tobramycin administer inhalation PARI eFlow rapid electronic nebulizer ( compressor ) vs. PARI LC PLUS Jet Nebulizer ( compressor ) subject cystic fibrosis .</brief_summary>
	<brief_title>Tobramycin Administered eFlow Rapid Nebulizer : Pharmacokinetic Study</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Male female subject age 6 year time screening , Chronically colonize Pseudomonas aeruginosa . Diagnosis cystic fibrosis ( CF ) Ability expectorate sputum sample command . Ability tolerate 1week washout interval inhale tobramycin aminoglycoside treatment . Clinically stable opinion investigator . Inhaled intravenous aminoglycosides within 7 day study drug administration . Any investigational drug within 2 week screen . Loop diuretic within 7 day study drug administration . Current use inhale tobramycin deliver PARI LC PLUS jet nebulizer without washout period least 1 week enter study . Women , plan become , pregnant course study . Serum creatinine blood urea ( BU ) upper limit normal sex age , abnormal urine analysis Known local systemic hypersensitivity aminoglycosides . Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Cystic fibrosis , tobramycin , PARI eFlow , PARI LC Plus , nebulizer , pharmacokinetic</keyword>
</DOC>